Fibrinogen is Associated with Clinical Adverse Events in Patients with Psoriasis and Coronary Artery Disease

References

• Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol. 1999;31(7):741–746. doi:10.1016/S1357-2725(99)00032-1
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799–1809. doi:10.1001/jama.294.14.1799
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–1320.
   PubMed Web of Science ®Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006;114(5):381–387. doi:10.1161/CIRCULATIONAHA.106.634089
   PubMed Web of Science ®Google Scholar
• Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol. 2013;61(1):23–34. doi:10.1016/j.jacc.2012.09.037
   PubMed Web of Science ®Google Scholar
• Mahmud E, Behnamfar O, Lin F, Reeves R, Patel M, Ang L. Elevated serum fibrinogen is associated with 12-month major adverse cardiovascular events following percutaneous coronary intervention. J Am Coll Cardiol. 2016;67(21):2556–2557. doi:10.1016/j.jacc.2016.03.540
   PubMed Web of Science ®Google Scholar
• Kim PY, Stewart RJ, Lipson SM, Nesheim ME. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost. 2007;5(6):1250–1256. doi:10.1111/j.1538-7836.2007.02426.x
   PubMed Web of Science ®Google Scholar
• Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014;112(1):32–42. doi:10.1160/TH14-01-0032
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511–520. doi:10.1182/blood-2018-07-818211
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, King L, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111(6):804–810. doi:10.1016/j.amjcard.2012.11.060
   PubMed Web of Science ®Google Scholar
• Chen WS, Chen SJ, Lee CC, Cherng WJ, Liu MH, Wang CH. Plasma P-selectin predicts long-term cardiovascular events in hospitalized patients with suspected coronary artery disease and preserved left ventricular function: a 10-year follow-up study. Biomed J. 2013;36(3):137–143. doi:10.4103/2319-4170.113231
   PubMedGoogle Scholar
• Sjöland H, Tengborn L, Stensdotter L, Herlitz J. Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery. Cardiology. 2007;108(2):82–89. doi:10.1159/000095935
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024. doi:10.1016/j.jaad.2013.06.053
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006. doi:10.1093/eurheartj/ehp567
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–592. doi:10.1111/j.1365-2133.2010.09941.x
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–e122. doi:10.1016/j.jacc.2011.08.007
   PubMed Web of Science ®Google Scholar
• Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(24):e123–e210. doi:10.1016/j.jacc.2011.08.009
   PubMed Web of Science ®Google Scholar
• Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32(5):442–458. doi:10.1002/dmrr.2827
   PubMed Web of Science ®Google Scholar
• Elenkova A, Matrozova J, Vasilev V, Robeva R, Zacharieva S. Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma/paraganglioma: retrospective single-center study. Ann Endocrinol. 2020;81(1):3–10. doi:10.1016/j.ando.2020.01.001
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357. doi:10.1161/HYPERTENSIONAHA.120.15026
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351. doi:10.1161/CIRCULATIONAHA.106.685313
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Xu N, Tang XF, Yao Y, et al. Association of Plasma Lipoprotein(a) with long-term adverse events in patients with chronic kidney disease who underwent percutaneous coronary intervention. Am J Cardiol. 2018;122(12):2043–2048. doi:10.1016/j.amjcard.2018.04.058
   PubMed Web of Science ®Google Scholar
• Meng Z, Zhao Y, He Y. Fibrinogen level predicts outcomes in critically ill patients with acute exacerbation of chronic heart failure. Dis Markers. 2021;2021:6639393. doi:10.1155/2021/6639393
   PubMed Web of Science ®Google Scholar
• Fricault P, Piot J, Estève C, et al. Preoperative fibrinogen level and postcardiac surgery morbidity and mortality rates. Ann Card Anaesth. 2022;25(4):485–489. doi:10.4103/aca.aca_103_21
   PubMed Web of Science ®Google Scholar
• Peng Y, Wang H, Li YM, et al. Relation between admission plasma fibrinogen levels and mortality in Chinese patients with coronary artery disease. Sci Rep. 2016;6:30506. doi:10.1038/srep30506
   PubMed Web of Science ®Google Scholar
• Song J, Yu T, Sun Z, Li Z, He D, Sun Z. Comparison of prognostic significance between serum fibrinogen and Global Registry of Acute Coronary Events score for prognosis of patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. Coron Artery Dis. 2020;31(2):124–129. doi:10.1097/MCA.0000000000000789
   PubMed Web of Science ®Google Scholar
• Sinning JM, Bickel C, Messow CM, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J. 2006;27(24):2962–2968. doi:10.1093/eurheartj/ehl362
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I, Epstein FH. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454. doi:10.1056/NEJM199902113400607
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695. doi:10.1056/NEJMra043430
   PubMed Web of Science ®Google Scholar
• Pretorius E. Platelets as potent signaling entities in type 2 diabetes mellitus. Trends Endocrinol Metabol. 2019;30(8):532–545. doi:10.1016/j.tem.2019.05.003
   PubMed Web of Science ®Google Scholar
• Naito M, Stirk CM, Smith EB, Thompson WD. Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. Thromb Res. 2000;98(2):165–174. doi:10.1016/S0049-3848(99)00202-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu C, Liu J, et al. Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study. Cardiovasc Diabetol. 2019;18(1):52. doi:10.1186/s12933-019-0858-5
   PubMed Web of Science ®Google Scholar
• Liu SL, Wu NQ, Shi HW, et al. Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020;19(1):36. doi:10.1186/s12933-020-01012-9
   PubMed Web of Science ®Google Scholar
• Yuan D, Jiang P, Zhu P, et al. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovasc Diabetol. 2021;20(1):143. doi:10.1186/s12933-021-01335-1
   PubMed Web of Science ®Google Scholar
• Yang SH, Du Y, Zhang Y, et al. Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ Open. 2017;7(6):e015041. doi:10.1136/bmjopen-2016-015041
   PubMed Web of Science ®Google Scholar
• Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63(3):1115–1123. doi:10.2337/db12-1625
   PubMed Web of Science ®Google Scholar
• Cook DG, Cappuccio FP, Atkinson RW, et al. Ethnic differences in fibrinogen levels: the role of environmental factors and the beta-fibrinogen gene. Am J Epidemiol. 2001;153(8):799–806. doi:10.1093/aje/153.8.799
   PubMed Web of Science ®Google Scholar
• Albert MA, Pare G, Morris A, et al. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from the Women’s Genome Health Study. Am Heart J. 2009;157(4):777–783.e771. doi:10.1016/j.ahj.2008.12.012
   PubMed Web of Science ®Google Scholar
• Albert MA, Glynn RJ, Buring JE, Ridker PM. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol. 2007;99(9):1246–1251. doi:10.1016/j.amjcard.2006.12.041
   PubMed Web of Science ®Google Scholar
• Güzel T, Aktan A, Demir M, Özbek M, Aslan B. Relationship between contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with chronic coronary total occlusion. Rev Assoc Med Bras. 2022;68(8):1078–1083. doi:10.1590/1806-9282.20220283
   PubMed Web of Science ®Google Scholar
• Guzel T, Bilik MZ, Arslan B, Kilic R, Aktan A. The effect of atherogenic plasma index on collateral development in patients with chronic coronary total occlusion. Exper Biomed Res. 2021;4(4):291–301. doi:10.30714/j-ebr.2021471924
   Google Scholar
• Aktan A, Güzel T, Özbek M, et al. The relationship between coronary collateral circulation and visceral fat. J Cardiovasc Med. 2021;9(1):1–12.
   Google Scholar
• Binti NN, Ferdausi N, Anik MEK, Islam LN, Cesaro A. Association of albumin, fibrinogen, and modified proteins with acute coronary syndrome. PLoS One. 2022;17(7):e0271882. doi:10.1371/journal.pone.0271882
   PubMed Web of Science ®Google Scholar
• Shi Y, Wu Y, Bian C, Zhang W, Yang J, Xu G. Predictive value of plasma fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010;37(2):178–183.
   PubMed Web of Science ®Google Scholar
• Choussat R, Montalescot G, Collet J, et al. Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol. 2000;86(4):379–384. doi:10.1016/S0002-9149(00)00950-4
   PubMed Web of Science ®Google Scholar
• Hsieh CT, Chien KL, Hsu HC, et al. Associations between fibrinogen levels and the risk of cardiovascular disease and all-cause death: a cohort study from the Chin-Shan community in Taiwan. BMJ Open. 2022;12(4):e054638. doi:10.1136/bmjopen-2021-054638
   PubMed Web of Science ®Google Scholar
• Jiang P, Gao Z, Zhao W, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chin Med J. 2019;132(8):914–921. doi:10.1097/CM9.0000000000000181
   PubMed Web of Science ®Google Scholar
• Zhao L, Sun L, Yang K, et al. Effects of metabolic syndrome on cardiovascular outcomes of psoriatic patients with coronary artery disease: a single center retrospective cohort study. Diabetes Metab Syndr Obes. 2023;16:1003–1012. doi:10.2147/DMSO.S402618
   PubMed Web of Science ®Google Scholar